-
17806-500An intermediate in the synthesis of dasatinib.
-
18582-1A selective inhibitor of 12-LO with an IC<sub>50</sub> value of 5.1 µM.
-
18582-10A selective inhibitor of 12-LO with an IC<sub>50</sub> value of 5.1 µM.
-
18582-25A selective inhibitor of 12-LO with an IC<sub>50</sub> value of 5.1 µM.
-
18582-5A selective inhibitor of 12-LO with an IC<sub>50</sub> value of 5.1 µM.
-
18905-1An orally bioavailable inhibitor of mPGES-1 (IC<sub>50</sub> = 0.24 µM in an in vitro human whole blood assay) inactive against COX-1 and COX-2 (9% inhibition at 100 µM and 16% at 30 µM, respectively).
-
18905-10An orally bioavailable inhibitor of mPGES-1 (IC<sub>50</sub> = 0.24 µM in an in vitro human whole blood assay) inactive against COX-1 and COX-2 (9% inhibition at 100 µM and 16% at 30 µM, respectively).
-
18905-5An orally bioavailable inhibitor of mPGES-1 (IC<sub>50</sub> = 0.24 µM in an in vitro human whole blood assay) inactive against COX-1 and COX-2 (9% inhibition at 100 µM and 16% at 30 µM, respectively).
-
18909-1An orally bioavailable inhibitor of sEH (IC<sub>50</sub> = 0.33 µM) and agonist of PPAR&gamma (EC<sub>50</sub> of 0.
-
18909-10An orally bioavailable inhibitor of sEH (IC<sub>50</sub> = 0.33 µM) and agonist of PPAR&gamma (EC<sub>50</sub> of 0.
-
18909-25An orally bioavailable inhibitor of sEH (IC<sub>50</sub> = 0.33 µM) and agonist of PPAR&gamma (EC<sub>50</sub> of 0.
-
18909-5An orally bioavailable inhibitor of sEH (IC<sub>50</sub> = 0.33 µM) and agonist of PPAR&gamma (EC<sub>50</sub> of 0.